Clinical Trials Directory

Trials / Unknown

UnknownNCT03842839

Effect of Tiotropium on Airway Remodeling in Patients With Early Stage COPD Accessed by Optical Coherence Tomography

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
100 (estimated)
Sponsor
Guangzhou Institute of Respiratory Disease · Academic / Other
Sex
All
Age
40 Years – 80 Years
Healthy volunteers
Not accepted

Summary

The study aims to explore the effect of tiotropium on airway remodeling by using Endobronchial Optical Coherence Tomography (EB-OCT). We enrolled patients with GOLD I stage COPD. All the patients will be divided into four groups randomly to receive SABA as needed with or without regular use of tiotropium. Changes of airway morphology (accessed by EB-OCT), pulmonary function, QOL, and SABA usage will be obtained.

Conditions

Interventions

TypeNameDescription
DRUGTiotropium Inhalation Powder [Spiriva] 0.018mgTiotropium bromide (Spiriva) capsule 18μg once daily inhaled.
DRUGSalbutamol sulphate aerosol (Ventolin) 0.01mgAs needed use of salbutamol sulphate aerosol (Ventolin) when exacerbation happens

Timeline

Start date
2018-10-01
Primary completion
2022-12-01
Completion
2022-12-01
First posted
2019-02-15
Last updated
2022-09-29

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT03842839. Inclusion in this directory is not an endorsement.